Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Semax | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Synthetic analog | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 316 | 436 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 9 (2 in people) | 3 (3 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | None registered | |
Shared outcomes
From the regulatory data of each peptide.
No FDA approval and no central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Noopept (omberacetam) | Semax |
|---|---|---|
| NeuroprotectionWhole body | 5212922 | 13014 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Receptor activity and mechanismPharmacology | 863452 | 5824331 |
|---|
| Cognition and memoryNervous system and cognition | 532501 | 31229 |
|---|
| Anxiety and moodNervous system and cognition | 20218 | 32131 |
|---|
| PharmacokineticsPharmacology | 18315 | 1275 |
|---|
| Inflammation markersImmune and inflammation | 12102 | 211191 |
|---|
| Immune responseImmune and inflammation | 1212 | 20182 |
|---|
| Brain and neuronal activityNervous system and cognition | 66 | 11 |
|---|
| Adverse eventsWhole body | 927 | 33 |
|---|
| Exercise and physical functionWhole body | 413 | 532 |
|---|
| Oxidative stressWhole body | 413 | 88 |
|---|
| Bleeding and clottingCardiovascular | 963 | 55 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semax differs from Corticotropin (ACTH) at 3 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Noopept (omberacetam) found in ClinicalTrials.gov.
No registered trial that tests Semax found in ClinicalTrials.gov.